Report Overview

The US Chronic Lymphocytic Leukemia therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Chronic lymphocytic leukemia (CLL) is slow-growing cancer which begins in lymphocytes in the bone marrow and extends into the blood. It can even spread to lymph nodes and other organs such as spleen and liver. Chronic lymphocytic leukemia is divided into two types, B-cell chronic lymphocytic leukemia and T- cell chronic lymphocytic leukemia. Symptoms of chronic lymphocytic leukemia include enlarged lymph nodes, fever, fatigue and pain in the abdomen due to an enlarged spleen, weight loss, night sweats, frequent infections, and others

Chronic lymphocytic leukemia is the most prevalent adult leukemia in the Western world, accounting for approximately 30% of all leukemias diagnosed in the United States. Approximately 14,600 new cases of CLL are expected to be diagnosed in the United States in 2015. As per the higher cost, the per-patient lifetime cost of CLL treatment will increase from $147,000 to $604,000 (310% increase) as oral targeted therapies become the first-line treatment. For patients enrolled in Medicare, the corresponding total out-of-pocket cost will increase from $9,200 to $57,000 (520% increase)



Market Growth Drivers and Restraints

The major factors driving the growth of the market is the prevalence of various cancers and the rise in the geriatric population. An increase in the investment by the key players in the pharmaceutical R&D sector is expected to boost the growth of the chronic lymphocytic leukemia market throughout the forecasted period

Higher cost of the patented drugs and therapies is the key for market growth. The stringent government regulations and inadequate reimbursement policies in US might hamper the market growth. Higher pricing of drugs outpaces the therapies too. The number of people in the US living with chronic lymphocytic leukemia, which is a rare blood and bone marrow disease, is forecast to reach 199,000 in 2025, up from 128,000 five years ago, thanks to more effective treatment. But a higher-priced pill, which is used as a first-line therapy and taken indefinitely, will also outpace the cost of chemotherapy, which has a fixed duration for treatment